Brokerages Expect Immune Design Corp (IMDZ) Will Post Quarterly Sales of $810,000.00

Wall Street analysts predict that Immune Design Corp (NASDAQ:IMDZ) will post sales of $810,000.00 for the current fiscal quarter, Zacks Investment Research reports. Two analysts have made estimates for Immune Design’s earnings, with the highest sales estimate coming in at $1.22 million and the lowest estimate coming in at $400,000.00. Immune Design posted sales of $2.06 million during the same quarter last year, which suggests a negative year over year growth rate of 60.7%. The firm is scheduled to announce its next quarterly earnings report on Tuesday, March 6th.

According to Zacks, analysts expect that Immune Design will report full year sales of $810,000.00 for the current year, with estimates ranging from $7.10 million to $9.00 million. For the next year, analysts expect that the firm will post sales of $16.37 million per share, with estimates ranging from $14.73 million to $18.00 million. Zacks’ sales averages are an average based on a survey of sell-side research firms that follow Immune Design.

A number of equities research analysts recently weighed in on the company. Wells Fargo & Co cut Immune Design from an “outperform” rating to a “market perform” rating and dropped their price target for the company from $29.00 to $10.00 in a research note on Tuesday, October 17th. ValuEngine cut Immune Design from a “sell” rating to a “strong sell” rating in a research note on Saturday, October 21st. Zacks Investment Research cut Immune Design from a “buy” rating to a “hold” rating in a research note on Friday, November 10th. Finally, Cowen restated a “buy” rating on shares of Immune Design in a research note on Monday, December 11th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and four have assigned a buy rating to the company. Immune Design has a consensus rating of “Hold” and a consensus target price of $13.06.

Shares of Immune Design (NASDAQ:IMDZ) opened at $3.55 on Thursday. Immune Design has a 12 month low of $2.90 and a 12 month high of $13.05. The stock has a market capitalization of $170.61, a P/E ratio of -1.67 and a beta of 2.03.

In other news, major shareholder Leo Guthart acquired 20,000 shares of the firm’s stock in a transaction on Monday, January 8th. The shares were purchased at an average cost of $3.90 per share, with a total value of $78,000.00. The purchase was disclosed in a filing with the SEC, which is available through this link. Also, CEO Carlos V. Paya sold 7,970 shares of the company’s stock in a transaction on Friday, January 5th. The shares were sold at an average price of $4.17, for a total value of $33,234.90. Following the completion of the transaction, the chief executive officer now directly owns 114,560 shares in the company, valued at $477,715.20. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 13,959 shares of company stock worth $58,209. Insiders own 20.70% of the company’s stock.

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Schwab Charles Investment Management Inc. grew its holdings in Immune Design by 59.7% in the 4th quarter. Schwab Charles Investment Management Inc. now owns 54,543 shares of the biotechnology company’s stock valued at $213,000 after buying an additional 20,400 shares in the last quarter. EAM Investors LLC acquired a new stake in shares of Immune Design during the 3rd quarter worth $387,000. Victory Capital Management Inc. grew its holdings in shares of Immune Design by 4.2% during the 3rd quarter. Victory Capital Management Inc. now owns 2,060,234 shares of the biotechnology company’s stock worth $21,324,000 after purchasing an additional 82,670 shares in the last quarter. California State Teachers Retirement System grew its holdings in shares of Immune Design by 8.3% during the 2nd quarter. California State Teachers Retirement System now owns 30,174 shares of the biotechnology company’s stock worth $294,000 after purchasing an additional 2,300 shares in the last quarter. Finally, Goldman Sachs Group Inc. acquired a new stake in shares of Immune Design during the 2nd quarter worth $291,000. 29.38% of the stock is currently owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY WARNING: “Brokerages Expect Immune Design Corp (IMDZ) Will Post Quarterly Sales of $810,000.00” was originally published by American Banking News and is the sole property of of American Banking News. If you are accessing this story on another publication, it was illegally stolen and reposted in violation of U.S. & international copyright and trademark legislation. The original version of this story can be viewed at https://www.americanbankingnews.com/2018/02/08/brokerages-expect-immune-design-corp-imdz-will-post-quarterly-sales-of-810000-00.html.

Immune Design Company Profile

Immune Design Corp. is a clinical-stage immunotherapy company. The Company is focused on cancer with in vivo approaches designed to enable the body’s immune system to fight disease. The Company has engineered its technologies to activate the immune system’s natural ability to create tumor-specific cytotoxic T cells (CTLs) to fight cancer.

Get a free copy of the Zacks research report on Immune Design (IMDZ)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Immune Design (NASDAQ:IMDZ)

Receive News & Ratings for Immune Design Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immune Design and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply